Shanghai Iluvatar Stock Surges After Upsized $902 Million Share Placement

Shares of Shanghai Iluvatar CoreX SemiCon Co. surged 7.1% to HK$600 on Thursday following the successful completion of an upsized share placement that raised significant capital for the company. The deal underscores strong investor confidence in the chipmaker's potential to capture domestic market share as Chinese technology firms seek alternatives to U.S. hardware.

Details of the Capital Raise

Iluvatar raised approximately HK$7.07 billion (about US$902 million) through the offering, exceeding its initial target of around $850 million. The placement, which occurred shortly after the company's six-month IPO lock-up period expired, involved the sale of 14.9 million new shares.

Key details of the transaction include:

• Placement Price: Shares were sold at HK$476 each, which represented a discount of roughly 15% to the previous session's closing price.
• Price Range: The final price was at the low end of the marketed range of HK$476 to HK$498.40.

Strategic Importance and Market Drivers

Ad

Investor enthusiasm for Iluvatar is being driven by a favorable geopolitical and commercial environment. U.S. export controls restricting access to advanced chips from companies like Nvidia have created a significant opportunity for domestic Chinese semiconductor firms.

Adding to this momentum are reports that Iluvatar is in discussions to supply at least 50,000 AI inference chips to ByteDance, a deal that would position it as a critical player in the hardware ecosystem of one of China's largest tech companies. The capital raised from the placement is expected to support the company's efforts to scale production and meet this growing demand.

Broader Context and Analyst View

The rally in Iluvatar's stock aligns with a broader positive sentiment for technology and AI-related companies listed in Hong Kong. The Hang Seng Tech Index recently posted strong gains, fueled by optimism around artificial intelligence and a rotation of capital into the sector.

Analyst sentiment for Iluvatar remains overwhelmingly positive. All six analysts covering the stock recommend a "Buy," contributing to a consensus "Strong Buy" rating. The average 12-month price target for the stock stands at HK$762.15, suggesting further potential upside from its current levels.